Cargando…

NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score

INTRODUCTION: Currently in China, many immune checkpoint inhibitors (ICIs) have been approved for the treatment of non-small cell lung cancer (NSCLC). Some patients can not benefit from ICIs, and approximately 50% of patients have immunotherapy-related toxicity. Therefore, it is necessary to monitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Peng, Yang, Dongliang, Cui, Xiaoxia, Wang, Hanping, Si, Xiaoyan, Zhang, Xiaotong, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381788/ https://www.ncbi.nlm.nih.gov/pubmed/32765097 http://dx.doi.org/10.2147/CMAR.S257967

Ejemplares similares

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients
por: Song, Peng, et al.
Publicado: (2020)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2020)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer
por: Liu, Ziwei, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease
por: Wang, Hanping, et al.
Publicado: (2019)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Histologic transformation of lung cancer during pembrolizumab therapy: A case report
por: Si, Xiaoyan, et al.
Publicado: (2020)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
por: Ni, Jun, et al.
Publicado: (2021)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Proteomics score: a potential biomarker for the prediction of prognosis in non-small cell lung cancer
por: Peng, Jie, et al.
Publicado: (2019)

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non‐small cell lung cancer
por: Xie, Hailun, et al.
Publicado: (2023)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy
por: Cheng, Tianli, et al.
Publicado: (2021)

Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
por: Sa, Huanlan, et al.
Publicado: (2019)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

The prognostic value of the Naples prognostic score for patients with non-small-cell lung cancer
por: Peng, Si-Min, et al.
Publicado: (2022)

Use of glucocorticoids in the management of immunotherapy‐related adverse effects
por: Wang, Hanping, et al.
Publicado: (2020)

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer
por: Zhang, Anqi, et al.
Publicado: (2022)

Prognostic Roles of Glucose to Lymphocyte Ratio and Modified Glasgow Prognosis Score in Patients With Non-small Cell Lung Cancer
por: Yang, Ming, et al.
Publicado: (2022)

Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
por: Zhao, Binghao, et al.
Publicado: (2017)

Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non‐small cell lung cancer
por: Deng, Jie, et al.
Publicado: (2022)

Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis
por: Zhu, Lucheng, et al.
Publicado: (2016)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
por: Si, Xiaoyan, et al.
Publicado: (2020)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer
por: Huang, Hao, et al.
Publicado: (2022)

Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
por: Guo, Hanfei, et al.
Publicado: (2021)

A prognostic model of non small cell lung cancer based on TCGA and ImmPort databases
por: Yang, Dongliang, et al.
Publicado: (2022)

Immunotherapy for Non-Small Cell Lung Cancer
por: Yoon, Sung Ho
Publicado: (2014)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
por: Luo, Jieyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ju995p3cknhf8q1brrc4ahtv20